CardiaCare (זיו הלת'קר)

Tel Aviv-Yafo, Israel

CardiaCare has developed a wearable therapy for atrial fibrillation. CardiaCare's technology utilizes noninvasive peripheral neuromodulation to mediate a cardiovascular anti-arrhythmic response that reduces atrial fibrillation burden. The technology employs a closed-loop approach, involving monitoring and therapy. The wearable wrist-band combines advanced ECG and PPG sensors with AI-based treatment algorithms to induce a neuromodulation stimulus. CardiaCare's neuromodulation of the median and ulnar nerves balances sympathetic (stellate) and parasympathetic (vagus) tone via the brachial plexus. This induces a cardiovascular anti-arrhythmic response, reduces premature atrial contractions, modulates heart rate and rhythm, and reduces atrial fibrillation triggers and burden. CardiaCare is based on multiple clinical observations with neuromodulation therapy in patients with atrial fibrillation. CardiaCare has completed a technical and clinical proof of concept and secured its intellectual property.

✓Source: HealthTech Alpha by Galen Growth

Shareable draft

Check out CardiaCare (זיו הלת'קר) on @MedStartr Today #AtrialFibrillation #Arrhythmias #CardiovascularDisease #Wearables #MedMo #MedStartrVentures

https://www.medstartr.ai/s/F4rbRPxYG14

Get Involved in CardiaCare (זיו הלת'קר)

🏢Is this your company? Claim This Profile

Join MedStartr to verify with your work email and edit this profile

Company Info

Founded: 2015
Website: my-cardiacare.com/

Disease Areas

Atrial Fibrillation Arrhythmias Cardiovascular Disease

Technologies

Wearable DevicesNoninvasiveNeuromodulationTherapeutic Devices

🌐Website

MedStartr Engagement Score

The MedStartr Index is a reflection of how the crowds that come to MedStartr everyday to find healthcare innovations reacted. Calculated by our AI agent Fyggy based on algorithms we have been building since 2012 and over 100 different factors, the math is proprietary and complex. Suffice to say, it has been found to be highly correlative with early stage company growth. What you see here is the public version. To learn more or to get deeper access to our predictive data on startup success for your fund or company, click here.

Comments

Comments from new members are shown once the company's team has approved them. Please follow the community rules.

Be the first to comment.

What do you think of CardiaCare (זיו הלת'קר)?

A HUGE part of what early stage companies, and even late stage ones, need and get on MedStartr is honest feedback from actual patients, clinicians, hospital leaders and industry insiders. It is very easy to get tunnel vision as a founder. Please tell the team that runs this company what you think.

Clinical Benefit Potential

The potential for a project to have a large and significant impact on medical care, treatment, or prevention.

Feasibility

The likelihood that this will provide benefit for patients / care givers and that the founders can execute on their vision and plan.

Innovativeness

The distinguishing features, concept, or technology that differentiates the entry compared to others that already exist and are in widespread use.

Fundability

The reviewers' beliefs that the idea is fundable or can make it to sustainability without outside investment.

Scalability

Some great ideas are destined to failure because they are too complex or too expensive. The reviewer should consider the likelihood that a project as explained, or perhaps with some tweaks, could possibly become a worldwide solution within a reasonable time frame.

Presentation Quality

How well the team presented the idea.

Submit anonymously — my name won't be shown to the team or on this profile

Your scores and comments are shown with your review on this company's profile.